These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 33448787)

  • 1. Development of a Non-IgG PD-1/PD-L1 Inhibitor by
    Ning B; Ren X; Hagiwara K; Takeoka S; Ito Y; Miyatake H
    ACS Chem Biol; 2021 Feb; 16(2):316-323. PubMed ID: 33448787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy.
    Zhang H; Xia Y; Yu C; Du H; Liu J; Li H; Huang S; Zhu Q; Xu Y; Zou Y
    Molecules; 2021 Jun; 26(11):. PubMed ID: 34199417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kaempferol and Its Glycoside, Kaempferol 7-O-Rhamnoside, Inhibit PD-1/PD-L1 Interaction In Vitro.
    Kim JH; Kim YS; Choi JG; Li W; Lee EJ; Park JW; Song J; Chung HS
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32375257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation of Biphenyl-Conjugated Bromotyrosine for Inhibition of PD-1/PD-L1 Immune Checkpoint Interactions.
    Kim EH; Kawamoto M; Dharmatti R; Kobatake E; Ito Y; Miyatake H
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32455628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural Characterization of a Macrocyclic Peptide Modulator of the PD-1/PD-L1 Immune Checkpoint Axis.
    Zyla E; Musielak B; Holak TA; Dubin G
    Molecules; 2021 Aug; 26(16):. PubMed ID: 34443436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Programmed Death Receptor-1/Programmed Death Ligand-1 Interactions by Ginsenoside Metabolites.
    Yim NH; Kim YS; Chung HS
    Molecules; 2020 Apr; 25(9):. PubMed ID: 32365500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity.
    Luan Y; Chai D; Peng J; Ma S; Wang M; Ma H; Li X; Fu S; Pan X; Wang X; Qin S; Xu T
    Int Immunopharmacol; 2016 Feb; 31():248-56. PubMed ID: 26773772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An in silico investigation on the binding site preference of PD-1 and PD-L1 for designing antibodies for targeted cancer therapy.
    Abdolmaleki S; Ganjalikhani Hakemi M; Ganjalikhany MR
    PLoS One; 2024; 19(7):e0304270. PubMed ID: 39052609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1/PD-1 axis as a potent therapeutic target in breast cancer.
    Bastaki S; Irandoust M; Ahmadi A; Hojjat-Farsangi M; Ambrose P; Hallaj S; Edalati M; Ghalamfarsa G; Azizi G; Yousefi M; Chalajour H; Jadidi-Niaragh F
    Life Sci; 2020 Apr; 247():117437. PubMed ID: 32070710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, evaluation, and SAR of 4-phenylindoline derivatives, a novel class of small-molecule inhibitors of the programmed cell death-1/ programmed cell death-ligand 1 (PD-1/PD-L1) interaction.
    Yang Y; Wang K; Chen H; Feng Z
    Eur J Med Chem; 2021 Feb; 211():113001. PubMed ID: 33272783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of immune checkpoints in the tumour-stromal microenvironment of sebaceous gland carcinoma.
    Singh L; Singh MK; Rizvi MA; Pushker N; Bakhshi S; Sen S; Kashyap S
    Br J Ophthalmol; 2021 Jan; 105(1):48-56. PubMed ID: 32277010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticancer Effect of
    Choi JG; Kim YS; Kim JH; Kim TI; Li W; Oh TW; Jeon CH; Kim SJ; Chung HS
    Front Immunol; 2020; 11():598556. PubMed ID: 33224152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Biphenyl Pyridines as Potent Small-Molecule Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction.
    Wang T; Cai S; Wang M; Zhang W; Zhang K; Chen D; Li Z; Jiang S
    J Med Chem; 2021 Jun; 64(11):7390-7403. PubMed ID: 34056906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy.
    Liu H; Zhao Z; Zhang L; Li Y; Jain A; Barve A; Jin W; Liu Y; Fetse J; Cheng K
    J Immunother Cancer; 2019 Oct; 7(1):270. PubMed ID: 31640814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computational Redesign of PD-1 Interface for PD-L1 Ligand Selectivity.
    Shrestha R; Garrett SC; Almo SC; Fiser A
    Structure; 2019 May; 27(5):829-836.e3. PubMed ID: 30930066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In silico screening and surface plasma resonance-based verification of programmed death 1-targeted peptides.
    Zhang P; Li C; Ji X; Gao M; Lyu S; Dai X; Du J
    Chem Biol Drug Des; 2020 Mar; 95(3):332-342. PubMed ID: 31755641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulators targeting the PD-1/PD-L1 protein-protein interaction: From antibodies to small molecules.
    Yang J; Hu L
    Med Res Rev; 2019 Jan; 39(1):265-301. PubMed ID: 30215856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2.
    Zak KM; Grudnik P; Magiera K; Dömling A; Dubin G; Holak TA
    Structure; 2017 Aug; 25(8):1163-1174. PubMed ID: 28768162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 Nanobody Competitively Inhibits the Formation of the PD-1/PD-L1 Complex: Comparative Molecular Dynamics Simulations.
    Sun X; Yan X; Zhuo W; Gu J; Zuo K; Liu W; Liang L; Gan Y; He G; Wan H; Gou X; Shi H; Hu J
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 29986511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of anti-feline PD-1 antibody and its functional analysis.
    Nishibori S; Kaneko MK; Nakagawa T; Nishigaki K; Kato Y; Igase M; Mizuno T
    Sci Rep; 2023 Apr; 13(1):6420. PubMed ID: 37095139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.